LSD1
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S7237 | OG-L002 | <1 mg/mL | 45 mg/mL | 19 mg/mL |
| S7574 | GSK-LSD1 2HCl | 57 mg/mL | 57 mg/mL | -1 mg/mL |
| S7795 | ORY-1001 (RG-6016) 2HCl | 61 mg/mL | 5 mg/mL | 4 mg/mL |
| S7796 | GSK2879552 2HCl | 44 mg/mL | 29 mg/mL | <1 mg/mL |
| S7680 | SP2509 | <1 mg/mL | 38 mg/mL | <1 mg/mL |
LSD1产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7237 |
OG-L002OG-L002是一种有效的，特异性LSD1抑制剂，无细胞试验中IC50为20 nM，比作用于MAO-B和MAO-A选择性分别高36和69倍。 |
Effect of treatment on equine herpesvirus type 1 (EHV-1) viral load during lytic infection of primary equine fetal kidney cells. At 24 hpi, reduced EHV-1 DNA copies per cell were detected in the presence of ganciclovir (**p = 0.0005) or OG-L002 (*p = 0.005), and markedly when both treatments (***p < 0.0001) were applied simultaneously in comparison with DMSO control vehicle. Combined treatment decreased the number of EHV-1 DNA copies in comparison to treatment with ganciclovir alone (p = 0.01) or OG-L002 alone (p = 0.001). Lines represent mean values.
|
|
| S7574 |
GSK-LSD1 2HClGSK-LSD1 2HCl是一种不可逆的选择性 LSD1抑制剂，IC50 为 16 nM，选择性比其它密切相关的FAD可利用酶(即 LSD2，MAO-A，MAO-B)高1000多倍。 |
||
| S7795 |
ORY-1001 (RG-6016) 2HClORY-1001 (RG-6016) 2HCl是一种口服具有活性的，选择性的，赖氨酸特异性脱甲基酶LSD1/KDM1A抑制剂，IC50为<20 nM，对相关的FAD依赖性氨基氧化酶具有高度选择性。Phase 1。 |
Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells.
|
|
| S7796 |
GSK2879552 2HClGSK2879552 2HCl 是一种有效的、选择性的、具有生物口服活性的、不可逆的LSD1的抑制剂，Kiapp=1.7 μM。 |
Effects of LSD1 inhibitors in acute myeloid leukaemia cells. Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells. Means±SEM of each two (caspase 3/7 activity) or three (flow cytometric analyses) separate measurements are shown.
|
|
| S7680 |
SP2509SP2509是一种选择性histone demethylase LSD1抑制剂，IC50为 13 nM，对MAO-A，MAO-B，乳酸脱氢酶和葡萄糖氧化酶没有活性。 |
Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells.
|
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S7237 |
OG-L002OG-L002是一种有效的，特异性LSD1抑制剂，无细胞试验中IC50为20 nM，比作用于MAO-B和MAO-A选择性分别高36和69倍。 |
Effect of treatment on equine herpesvirus type 1 (EHV-1) viral load during lytic infection of primary equine fetal kidney cells. At 24 hpi, reduced EHV-1 DNA copies per cell were detected in the presence of ganciclovir (**p = 0.0005) or OG-L002 (*p = 0.005), and markedly when both treatments (***p < 0.0001) were applied simultaneously in comparison with DMSO control vehicle. Combined treatment decreased the number of EHV-1 DNA copies in comparison to treatment with ganciclovir alone (p = 0.01) or OG-L002 alone (p = 0.001). Lines represent mean values.
|
|
| S7574 |
GSK-LSD1 2HClGSK-LSD1 2HCl是一种不可逆的选择性 LSD1抑制剂，IC50 为 16 nM，选择性比其它密切相关的FAD可利用酶(即 LSD2，MAO-A，MAO-B)高1000多倍。 |
||
| S7795 |
ORY-1001 (RG-6016) 2HClORY-1001 (RG-6016) 2HCl是一种口服具有活性的，选择性的，赖氨酸特异性脱甲基酶LSD1/KDM1A抑制剂，IC50为<20 nM，对相关的FAD依赖性氨基氧化酶具有高度选择性。Phase 1。 |
Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells.
|
|
| S7796 |
GSK2879552 2HClGSK2879552 2HCl 是一种有效的、选择性的、具有生物口服活性的、不可逆的LSD1的抑制剂，Kiapp=1.7 μM。 |
Effects of LSD1 inhibitors in acute myeloid leukaemia cells. Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells. Means±SEM of each two (caspase 3/7 activity) or three (flow cytometric analyses) separate measurements are shown.
|
|
| S7680 |
SP2509SP2509是一种选择性histone demethylase LSD1抑制剂，IC50为 13 nM，对MAO-A，MAO-B，乳酸脱氢酶和葡萄糖氧化酶没有活性。 |
Cells were exposed to drugs for 48 h or for the indicated times. Cell death and Dwm dissipation were determined by flow cytometric analyses of propidium iodide uptake or DiOC6(3) staining, respectively. Caspase 3/7 activity was determined using the fluorogenic substrate Ac-DEVD-AMC; relative caspase 3/7 activities are the ratio of treated cells to untreated cells.
|
